Drug
XY0206
XY0206 is a pharmaceutical drug with 4 clinical trials. Currently 1 active trials ongoing.
Total Trials
4
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Active Trials
1(25%)
Phase Distribution
Ph phase_1
3
75%
Ph phase_3
1
25%
Phase Distribution
3
Early Stage
0
Mid Stage
1
Late Stage
Phase Distribution4 total trials
Phase 1Safety & dosage
3(75.0%)
Phase 3Large-scale testing
1(25.0%)
Highest Phase Reached
Phase 3Trial Status & Enrollment
Completion Rate
0.0%
0 of 0 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
1
trials recruiting
Total Trials
4
all time
Status Distribution
Active(2)
Other(2)
Detailed Status
unknown2
Recruiting1
Not yet recruiting1
Development Timeline
Analytics
Development Status
Total Trials
4
Active
1
Success Rate
N/A
Most Advanced
Phase 3
Trials by Phase
Phase 13 (75.0%)
Phase 31 (25.0%)
Trials by Status
unknown250%
recruiting125%
not_yet_recruiting125%
Recent Activity
1 active trials
Showing 4 of 4
recruitingphase_1
A Study to Evaluate the Effect of XY0206 on the QTc Interval in Chinese Healthy Participants
NCT07162116
not_yet_recruitingphase_3
A Study of XY0206 Versus Salvage Chemotherapy In Patients With Relapsed or Refractory AML With FLT3-ITD-Mutation (ALIVE)
NCT05876832
unknownphase_1
A Study of XY0206 Tablets in Patients With Relapsed / Refractory Acute Myeloid Leukemia
NCT04471064
unknownphase_1
A Study of XY0206 in Subjects With Advanced or Metastatic Solid Tumours
NCT03658070
Clinical Trials (4)
Showing 4 of 4 trials
NCT07162116Phase 1
A Study to Evaluate the Effect of XY0206 on the QTc Interval in Chinese Healthy Participants
NCT05876832Phase 3
A Study of XY0206 Versus Salvage Chemotherapy In Patients With Relapsed or Refractory AML With FLT3-ITD-Mutation (ALIVE)
NCT04471064Phase 1
A Study of XY0206 Tablets in Patients With Relapsed / Refractory Acute Myeloid Leukemia
NCT03658070Phase 1
A Study of XY0206 in Subjects With Advanced or Metastatic Solid Tumours
All 4 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 4